Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMNN with free AI briefings, catalyst countdowns, and dilution alerts.

IMNN · Imunon, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4M Cash on Hand
3.9mo Cash Runway
Follow IMNN by email Get an email when IMNN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMNN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
5% Dextrose Solution Hepatocellular Carcinoma Phase 3 · NCT00617981 Completed
Lyso-Thermosensitive Liposome Doxorubicin Hepatocellular Carcinoma Phase 3 · NCT02112656 Completed
Dummy Infusion Hepatocellular Carcinoma Phase 3 · NCT02112656 Completed
PEG-PEI-cholesterol Lipopolymer-encased IL-12… Epithelial Ovarian Cancer Phase 3 · NCT06915025 Recruiting
ThermoDox in combination with Microwave… Breast Cancer Phase 1/2 · NCT00826085 Completed
Doxorubicin Colon Cancer Liver Metastasis Phase 2 · NCT01464593 Terminated
IMNN-101 SARS CoV 2 Infection Phase 1/2 · NCT06283459 Completed
Pegylated Liposomal Doxorubicin Hydrochloride Prostate Cancer Phase 1 · NCT00061867 Completed

Also used in these trials (approved or third-party drugs, not IMNN's own candidates): Carboplatin, Paclitaxel, Olaparib, Niraparib, Bevacizumab, Doxorubicin Hydrochloride, Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMNN holds $4M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.1M/quarter from operations, an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMNN files for a raise →

👥 Who Owns IMNN

Insiders 7.1% Institutions (24 holders) 5.9% Public and other holders 87%
HolderTypeShares% of sharesAs of
Michael H Tardugno
Executive Chairman of Board, Director
Insider 133,133 2.05% 2026-11-06
Stacy Lindborg
President and CEO, Director
Insider 123,359 1.90% 2026-11-06
Douglas Vincent Faller
Chief Medical Officer
Insider 76,356 1.18% 2026-11-06
James E Dentzer
Director
Insider 34,197 0.53% 2026-11-06
Donald P Braun
Director
Insider 33,643 0.52% 2026-11-06
Christine A Pellizzari
Director
Insider 28,665 0.44% 2026-11-06
Frederick J. Fritz
Director
Insider 28,242 0.44% 2026-11-06
Susan Eylward
General Counsel and Corp Sec
Insider 2,896 0.04% 2026-08-28

Share count 6,487,286 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMNN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMNN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.